UK industry challenges generalisation of studies slamming monitoring
This article was originally published in Clinica
Executive Summary
Researchers questioning the clinical value and cost-effectiveness of blood glucose self-monitoring in type 2 (non-insulin-dependent) diabetes have rekindled a decade-long debate on the issue. The main findings of two studies published today by the British Medical Journal (BMJ) are that routine testing may be wasting around £100m ($198m) a year, with little glycaemic control benefit and, reputedly, worse quality of life.